GlobeNewswire Inc.··Mbx Biosciences, Inc.MBX Biosciences Advances Obesity Pipeline with Once-Monthly GLP-1/GIP Drug Candidate
MBX Biosciences reports Phase 1 data for obesity candidate MBX 4291 showing 7% weight loss with once-monthly potential; advances four-agonist MBX 5765.
MBXweight lossPhase 1 clinical trial